Literature DB >> 15501456

Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling.

Dinesh Ranjan1, Changguo Chen, Thomas D Johnston, Hoonbae Jeon, Moolky Nagabhushan.   

Abstract

BACKGROUND: T cell mediated acute rejection of transplanted organ continues to be a noticeable problem in solid organ transplantation. We showed that Curcumin is a potent inhibitor of Cyclosporin A resistant T cell CD28 co-stimulation pathway. Here we report the inhibitory effects of Curcumin on mitogen-stimulated lymphocyte proliferation, IL-2 synthesis/signaling, and NFkappaB (transcription factor of IL-2 promoter) activation.
MATERIALS AND METHODS: Human lymphocytes were isolated from fresh human spleen (SP-L). Mitogens [final concentrations of 2 microg/ml concanavalin A (Con A), 5 microg/ml phytohemagglutinin (PHA), and 20 ng/ml of phorbol-12-myristate-13-acetate (PMA)] were added to the designated wells in a 96-well plate with 0.2 million SP-L and cultured for 48 h and then assayed for IL-2 synthesis by ELISA and 3H-thymidine uptake. In another parallel experiment we added IL-2 (0.5 nM) to stimulate the cells to check if Curcumin's inhibition of IL-2 synthesis is the sole reason for inhibition of cell proliferation. Electrophoretic mobility shift assay (EMSA) was performed in PMA (20 ng/ml, 1 h) stimulated cells with or without Curcumin to assay NFkappaB activation.
RESULTS: Curcumin at 2.5 microg/ml inhibited Con A, PHA, and PMA stimulated SP-L proliferation at 77, 23, and 48%, respectively, over controls and Curcumin at 5 microg/ml completely (nearly 100%) inhibited the mitogen stimulated proliferation. Curcumin inhibited IL-2 synthesis in Con A, PHA, and PMA stimulated SP-L in a concentration-dependent manner with an ED50 (concentration required for 50% inhibition) measured at 3.5 microg/ml. Exogenous IL-2 stimulated SP-L proliferation was also inhibited by Curcumin in a concentration-dependent manner with an ED50 of 2 microg/ml. EMSA assay indicated that PMA at 20 ng/ml stimulated NFkappaB activation 253% over control, which was inhibited by 24, 38, and 73%, respectively, with Curcumin at final concentrations of 2.5, 5, and 10 microg/ml, respectively.
CONCLUSION: Curcumin has profound immunosuppressive effects mediated via inhibition of IL-2 synthesis, mitogen, and IL-2 induced activation of human lymphocytes. This effect may be mediated via NFkappaB inhibition. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501456     DOI: 10.1016/j.jss.2004.04.004

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  30 in total

1.  Curcumin suppresses T cell activation by blocking Ca2+ mobilization and nuclear factor of activated T cells (NFAT) activation.

Authors:  Christian Kliem; Anette Merling; Marco Giaisi; Rebecca Köhler; Peter H Krammer; Min Li-Weber
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

2.  Clinical comparison of dose calculation using the enhanced collapsed cone algorithm vs. a new Monte Carlo algorithm.

Authors:  Irina Fotina; Gabriele Kragl; Bernhard Kroupa; Robert Trausmuth; Dietmar Georg
Journal:  Strahlenther Onkol       Date:  2011-06-27       Impact factor: 3.621

3.  Curcumin disrupts meiotic and mitotic divisions via spindle impairment and inhibition of CDK1 activity.

Authors:  A Bielak-Zmijewska; M Sikora-Polaczek; K Nieznanski; G Mosieniak; A Kolano; M Maleszewski; J Styrna; E Sikora
Journal:  Cell Prolif       Date:  2010-08       Impact factor: 6.831

Review 4.  "Spicing up" of the immune system by curcumin.

Authors:  Ganesh Chandra Jagetia; Bharat B Aggarwal
Journal:  J Clin Immunol       Date:  2007-01-09       Impact factor: 8.317

5.  Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth.

Authors:  Shui Ping Tu; Huanyu Jin; Jin Dong Shi; Li Ming Zhu; Ya Suo; Gang Lu; Anna Liu; Timothy C Wang; Chung S Yang
Journal:  Cancer Prev Res (Phila)       Date:  2011-10-26

6.  Proximal human FOXP3 promoter transactivated by NF-kappaB and negatively controlled by feedback loop and SP3.

Authors:  Paul Eckerstorfer; Michael Novy; Sebastian Burgstaller-Muehlbacher; Wolfgang Paster; Herbert B Schiller; Herbert Mayer; Hannes Stockinger
Journal:  Mol Immunol       Date:  2010-05-11       Impact factor: 4.407

7.  Curcumin attenuates ischemia-like injury induced IL-1β elevation in brain microvascular endothelial cells via inhibiting MAPK pathways and nuclear factor-κB activation.

Authors:  Hua-Jiang Dong; Chong-Zhi Shang; Ding-Wei Peng; Jian Xu; Peng-Xiao Xu; Li Zhan; Peng Wang
Journal:  Neurol Sci       Date:  2014-03-21       Impact factor: 3.307

Review 8.  Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities.

Authors:  Petros Efthimiou; Manil Kukar
Journal:  Rheumatol Int       Date:  2009-10-30       Impact factor: 2.631

9.  Inhibition of human dendritic cell activation by hydroethanolic but not lipophilic extracts of turmeric (Curcuma longa).

Authors:  Joseph Krasovsky; David H Chang; Gary Deng; Simon Yeung; Mavis Lee; Ping Chung Leung; Susanna Cunningham-Rundles; Barrie Cassileth; Madhav V Dhodapkar
Journal:  Planta Med       Date:  2008-11-25       Impact factor: 3.352

Review 10.  Perspectives on new synthetic curcumin analogs and their potential anticancer properties.

Authors:  Alok Vyas; Prasad Dandawate; Subhash Padhye; Aamir Ahmad; Fazlul Sarkar
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.